HIV pretreatment drug resistance trends in three geographic areas of Mexico
Pretreatment drug resistance (PDR) levels to NNRTI approaching 10% have recently been reported in Mexico. However, subnational differences may exist in PDR prevalence and transmission dynamics. We longitudinally assessed HIV PDR in three geographic areas of Mexico. HIV-infected, antiretroviral-naive...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 2017-11, Vol.72 (11), p.3149-3158 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3158 |
|---|---|
| container_issue | 11 |
| container_start_page | 3149 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 72 |
| creator | García-Morales, Claudia Tapia-Trejo, Daniela Quiroz-Morales, Verónica S Navarro-Álvarez, Samuel Barrera-Arellano, Carlos A Casillas-Rodríguez, Jesús Romero-Mora, Karla A Gómez-Palacio-Schjetnan, María Murakami-Ogasawara, Akio Ávila-Ríos, Santiago Reyes-Terán, Gustavo |
| description | Pretreatment drug resistance (PDR) levels to NNRTI approaching 10% have recently been reported in Mexico. However, subnational differences may exist in PDR prevalence and transmission dynamics.
We longitudinally assessed HIV PDR in three geographic areas of Mexico.
HIV-infected, antiretroviral-naive individuals were recruited from 2008 to 2016, from the Central Metropolitan Zone (CMZ), Cancun and Tijuana (1194, 773 and 668 respectively). PDR was estimated using the Stanford HIVdb tool from plasma HIV pol sequences.
A higher proportion of females, lower education and lower employment rate were observed in Tijuana, while a higher proportion of MSM was observed in the CMZ (P |
| doi_str_mv | 10.1093/jac/dkx281 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1945220554</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1945220554</sourcerecordid><originalsourceid>FETCH-LOGICAL-c287t-7f90e159ad23ed838fa8a5abc31aa7c02eef7344566d10c013d6a676c2d3fc813</originalsourceid><addsrcrecordid>eNo9kD1PwzAURS0EoqWw8AOQR4QU-mzHjjOiCiiiiAVYI9d-aVOaD2xHKv-eoBamO9xz73AIuWRwyyAX042xU_e545odkTFLFSQccnZMxiBAJlkqxYichbABACWVPiUjrnPF8oyPyfP86YN2HqNHE2tsInW-X1GPoQrRNBbp0DQu0Kqhce0R6QrblTfdurLUDKNA25K-4K6y7Tk5Kc024MUhJ-T94f5tNk8Wr49Ps7tFYrnOYpKVOSCTuXFcoNNCl0YbaZZWMGMyCxyxzESaSqUcAwtMOGVUpix3orSaiQm53v92vv3qMcSiroLF7dY02PahYHkqOQcp0wG92aPWtyF4LIvOV7Xx3wWD4ldeMcgr9vIG-Orw2y9rdP_ony3xA3tZa34</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1945220554</pqid></control><display><type>article</type><title>HIV pretreatment drug resistance trends in three geographic areas of Mexico</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>García-Morales, Claudia ; Tapia-Trejo, Daniela ; Quiroz-Morales, Verónica S ; Navarro-Álvarez, Samuel ; Barrera-Arellano, Carlos A ; Casillas-Rodríguez, Jesús ; Romero-Mora, Karla A ; Gómez-Palacio-Schjetnan, María ; Murakami-Ogasawara, Akio ; Ávila-Ríos, Santiago ; Reyes-Terán, Gustavo</creator><creatorcontrib>García-Morales, Claudia ; Tapia-Trejo, Daniela ; Quiroz-Morales, Verónica S ; Navarro-Álvarez, Samuel ; Barrera-Arellano, Carlos A ; Casillas-Rodríguez, Jesús ; Romero-Mora, Karla A ; Gómez-Palacio-Schjetnan, María ; Murakami-Ogasawara, Akio ; Ávila-Ríos, Santiago ; Reyes-Terán, Gustavo ; HIVDR MexNet Group ; on behalf of the HIVDR MexNet Group</creatorcontrib><description>Pretreatment drug resistance (PDR) levels to NNRTI approaching 10% have recently been reported in Mexico. However, subnational differences may exist in PDR prevalence and transmission dynamics.
We longitudinally assessed HIV PDR in three geographic areas of Mexico.
HIV-infected, antiretroviral-naive individuals were recruited from 2008 to 2016, from the Central Metropolitan Zone (CMZ), Cancun and Tijuana (1194, 773 and 668 respectively). PDR was estimated using the Stanford HIVdb tool from plasma HIV pol sequences.
A higher proportion of females, lower education and lower employment rate were observed in Tijuana, while a higher proportion of MSM was observed in the CMZ (P < 0.0001, all cases). For 2012-16, PDR was 13.4%, 8.9% and 11.2% in the CMZ, Tijuana and Cancun respectively. NNRTI PDR was highest in the three regions (8.7%, 4.8% and 8.1% respectively, P < 0.05); nevertheless, NNRTI PDR in Tijuana was lower than in the CMZ (P = 0.01). For 2008-16, we observed increasing efavirenz resistance trends in all regions (P < 0.05, all cases), reaching 11.8%, 6.1% and 8.3% respectively in 2016. Increasing efavirenz resistance was mostly associated with increasing K103N frequency (P = 0.007 CMZ, P = 0.03 Tijuana, not significant for Cancun).
Our study suggests different NNRTI PDR prevalence and transmission dynamics in three geographical areas of Mexico. Even when increasing trends in efavirenz resistance were observed in the three areas, our observations support that, in a large country such as Mexico, subnational surveillance and locally tailored interventions to address drug resistance may be a reasonable option.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkx281</identifier><identifier>PMID: 28961972</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Alkynes ; Anti-HIV Agents - pharmacology ; Anti-HIV Agents - therapeutic use ; Benzoxazines - pharmacology ; Cross-Sectional Studies ; Cyclopropanes ; Drug Resistance, Multiple, Viral ; Epidemiological Monitoring ; Female ; Genotype ; Geography ; HIV Infections - drug therapy ; HIV Infections - epidemiology ; HIV Infections - transmission ; HIV Infections - virology ; HIV-1 - drug effects ; HIV-1 - genetics ; Humans ; Male ; Mexico - epidemiology ; Mutation ; Prevalence ; Retrospective Studies ; Reverse Transcriptase Inhibitors - pharmacology ; Reverse Transcriptase Inhibitors - therapeutic use ; Sequence Analysis, DNA ; Young Adult</subject><ispartof>Journal of antimicrobial chemotherapy, 2017-11, Vol.72 (11), p.3149-3158</ispartof><rights>The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c287t-7f90e159ad23ed838fa8a5abc31aa7c02eef7344566d10c013d6a676c2d3fc813</citedby><cites>FETCH-LOGICAL-c287t-7f90e159ad23ed838fa8a5abc31aa7c02eef7344566d10c013d6a676c2d3fc813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28961972$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>García-Morales, Claudia</creatorcontrib><creatorcontrib>Tapia-Trejo, Daniela</creatorcontrib><creatorcontrib>Quiroz-Morales, Verónica S</creatorcontrib><creatorcontrib>Navarro-Álvarez, Samuel</creatorcontrib><creatorcontrib>Barrera-Arellano, Carlos A</creatorcontrib><creatorcontrib>Casillas-Rodríguez, Jesús</creatorcontrib><creatorcontrib>Romero-Mora, Karla A</creatorcontrib><creatorcontrib>Gómez-Palacio-Schjetnan, María</creatorcontrib><creatorcontrib>Murakami-Ogasawara, Akio</creatorcontrib><creatorcontrib>Ávila-Ríos, Santiago</creatorcontrib><creatorcontrib>Reyes-Terán, Gustavo</creatorcontrib><creatorcontrib>HIVDR MexNet Group</creatorcontrib><creatorcontrib>on behalf of the HIVDR MexNet Group</creatorcontrib><title>HIV pretreatment drug resistance trends in three geographic areas of Mexico</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Pretreatment drug resistance (PDR) levels to NNRTI approaching 10% have recently been reported in Mexico. However, subnational differences may exist in PDR prevalence and transmission dynamics.
We longitudinally assessed HIV PDR in three geographic areas of Mexico.
HIV-infected, antiretroviral-naive individuals were recruited from 2008 to 2016, from the Central Metropolitan Zone (CMZ), Cancun and Tijuana (1194, 773 and 668 respectively). PDR was estimated using the Stanford HIVdb tool from plasma HIV pol sequences.
A higher proportion of females, lower education and lower employment rate were observed in Tijuana, while a higher proportion of MSM was observed in the CMZ (P < 0.0001, all cases). For 2012-16, PDR was 13.4%, 8.9% and 11.2% in the CMZ, Tijuana and Cancun respectively. NNRTI PDR was highest in the three regions (8.7%, 4.8% and 8.1% respectively, P < 0.05); nevertheless, NNRTI PDR in Tijuana was lower than in the CMZ (P = 0.01). For 2008-16, we observed increasing efavirenz resistance trends in all regions (P < 0.05, all cases), reaching 11.8%, 6.1% and 8.3% respectively in 2016. Increasing efavirenz resistance was mostly associated with increasing K103N frequency (P = 0.007 CMZ, P = 0.03 Tijuana, not significant for Cancun).
Our study suggests different NNRTI PDR prevalence and transmission dynamics in three geographical areas of Mexico. Even when increasing trends in efavirenz resistance were observed in the three areas, our observations support that, in a large country such as Mexico, subnational surveillance and locally tailored interventions to address drug resistance may be a reasonable option.</description><subject>Adult</subject><subject>Alkynes</subject><subject>Anti-HIV Agents - pharmacology</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Benzoxazines - pharmacology</subject><subject>Cross-Sectional Studies</subject><subject>Cyclopropanes</subject><subject>Drug Resistance, Multiple, Viral</subject><subject>Epidemiological Monitoring</subject><subject>Female</subject><subject>Genotype</subject><subject>Geography</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - epidemiology</subject><subject>HIV Infections - transmission</subject><subject>HIV Infections - virology</subject><subject>HIV-1 - drug effects</subject><subject>HIV-1 - genetics</subject><subject>Humans</subject><subject>Male</subject><subject>Mexico - epidemiology</subject><subject>Mutation</subject><subject>Prevalence</subject><subject>Retrospective Studies</subject><subject>Reverse Transcriptase Inhibitors - pharmacology</subject><subject>Reverse Transcriptase Inhibitors - therapeutic use</subject><subject>Sequence Analysis, DNA</subject><subject>Young Adult</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kD1PwzAURS0EoqWw8AOQR4QU-mzHjjOiCiiiiAVYI9d-aVOaD2xHKv-eoBamO9xz73AIuWRwyyAX042xU_e545odkTFLFSQccnZMxiBAJlkqxYichbABACWVPiUjrnPF8oyPyfP86YN2HqNHE2tsInW-X1GPoQrRNBbp0DQu0Kqhce0R6QrblTfdurLUDKNA25K-4K6y7Tk5Kc024MUhJ-T94f5tNk8Wr49Ps7tFYrnOYpKVOSCTuXFcoNNCl0YbaZZWMGMyCxyxzESaSqUcAwtMOGVUpix3orSaiQm53v92vv3qMcSiroLF7dY02PahYHkqOQcp0wG92aPWtyF4LIvOV7Xx3wWD4ldeMcgr9vIG-Orw2y9rdP_ony3xA3tZa34</recordid><startdate>20171101</startdate><enddate>20171101</enddate><creator>García-Morales, Claudia</creator><creator>Tapia-Trejo, Daniela</creator><creator>Quiroz-Morales, Verónica S</creator><creator>Navarro-Álvarez, Samuel</creator><creator>Barrera-Arellano, Carlos A</creator><creator>Casillas-Rodríguez, Jesús</creator><creator>Romero-Mora, Karla A</creator><creator>Gómez-Palacio-Schjetnan, María</creator><creator>Murakami-Ogasawara, Akio</creator><creator>Ávila-Ríos, Santiago</creator><creator>Reyes-Terán, Gustavo</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20171101</creationdate><title>HIV pretreatment drug resistance trends in three geographic areas of Mexico</title><author>García-Morales, Claudia ; Tapia-Trejo, Daniela ; Quiroz-Morales, Verónica S ; Navarro-Álvarez, Samuel ; Barrera-Arellano, Carlos A ; Casillas-Rodríguez, Jesús ; Romero-Mora, Karla A ; Gómez-Palacio-Schjetnan, María ; Murakami-Ogasawara, Akio ; Ávila-Ríos, Santiago ; Reyes-Terán, Gustavo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c287t-7f90e159ad23ed838fa8a5abc31aa7c02eef7344566d10c013d6a676c2d3fc813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Alkynes</topic><topic>Anti-HIV Agents - pharmacology</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Benzoxazines - pharmacology</topic><topic>Cross-Sectional Studies</topic><topic>Cyclopropanes</topic><topic>Drug Resistance, Multiple, Viral</topic><topic>Epidemiological Monitoring</topic><topic>Female</topic><topic>Genotype</topic><topic>Geography</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - epidemiology</topic><topic>HIV Infections - transmission</topic><topic>HIV Infections - virology</topic><topic>HIV-1 - drug effects</topic><topic>HIV-1 - genetics</topic><topic>Humans</topic><topic>Male</topic><topic>Mexico - epidemiology</topic><topic>Mutation</topic><topic>Prevalence</topic><topic>Retrospective Studies</topic><topic>Reverse Transcriptase Inhibitors - pharmacology</topic><topic>Reverse Transcriptase Inhibitors - therapeutic use</topic><topic>Sequence Analysis, DNA</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García-Morales, Claudia</creatorcontrib><creatorcontrib>Tapia-Trejo, Daniela</creatorcontrib><creatorcontrib>Quiroz-Morales, Verónica S</creatorcontrib><creatorcontrib>Navarro-Álvarez, Samuel</creatorcontrib><creatorcontrib>Barrera-Arellano, Carlos A</creatorcontrib><creatorcontrib>Casillas-Rodríguez, Jesús</creatorcontrib><creatorcontrib>Romero-Mora, Karla A</creatorcontrib><creatorcontrib>Gómez-Palacio-Schjetnan, María</creatorcontrib><creatorcontrib>Murakami-Ogasawara, Akio</creatorcontrib><creatorcontrib>Ávila-Ríos, Santiago</creatorcontrib><creatorcontrib>Reyes-Terán, Gustavo</creatorcontrib><creatorcontrib>HIVDR MexNet Group</creatorcontrib><creatorcontrib>on behalf of the HIVDR MexNet Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García-Morales, Claudia</au><au>Tapia-Trejo, Daniela</au><au>Quiroz-Morales, Verónica S</au><au>Navarro-Álvarez, Samuel</au><au>Barrera-Arellano, Carlos A</au><au>Casillas-Rodríguez, Jesús</au><au>Romero-Mora, Karla A</au><au>Gómez-Palacio-Schjetnan, María</au><au>Murakami-Ogasawara, Akio</au><au>Ávila-Ríos, Santiago</au><au>Reyes-Terán, Gustavo</au><aucorp>HIVDR MexNet Group</aucorp><aucorp>on behalf of the HIVDR MexNet Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HIV pretreatment drug resistance trends in three geographic areas of Mexico</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2017-11-01</date><risdate>2017</risdate><volume>72</volume><issue>11</issue><spage>3149</spage><epage>3158</epage><pages>3149-3158</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><abstract>Pretreatment drug resistance (PDR) levels to NNRTI approaching 10% have recently been reported in Mexico. However, subnational differences may exist in PDR prevalence and transmission dynamics.
We longitudinally assessed HIV PDR in three geographic areas of Mexico.
HIV-infected, antiretroviral-naive individuals were recruited from 2008 to 2016, from the Central Metropolitan Zone (CMZ), Cancun and Tijuana (1194, 773 and 668 respectively). PDR was estimated using the Stanford HIVdb tool from plasma HIV pol sequences.
A higher proportion of females, lower education and lower employment rate were observed in Tijuana, while a higher proportion of MSM was observed in the CMZ (P < 0.0001, all cases). For 2012-16, PDR was 13.4%, 8.9% and 11.2% in the CMZ, Tijuana and Cancun respectively. NNRTI PDR was highest in the three regions (8.7%, 4.8% and 8.1% respectively, P < 0.05); nevertheless, NNRTI PDR in Tijuana was lower than in the CMZ (P = 0.01). For 2008-16, we observed increasing efavirenz resistance trends in all regions (P < 0.05, all cases), reaching 11.8%, 6.1% and 8.3% respectively in 2016. Increasing efavirenz resistance was mostly associated with increasing K103N frequency (P = 0.007 CMZ, P = 0.03 Tijuana, not significant for Cancun).
Our study suggests different NNRTI PDR prevalence and transmission dynamics in three geographical areas of Mexico. Even when increasing trends in efavirenz resistance were observed in the three areas, our observations support that, in a large country such as Mexico, subnational surveillance and locally tailored interventions to address drug resistance may be a reasonable option.</abstract><cop>England</cop><pmid>28961972</pmid><doi>10.1093/jac/dkx281</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 2017-11, Vol.72 (11), p.3149-3158 |
| issn | 0305-7453 1460-2091 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1945220554 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | Adult Alkynes Anti-HIV Agents - pharmacology Anti-HIV Agents - therapeutic use Benzoxazines - pharmacology Cross-Sectional Studies Cyclopropanes Drug Resistance, Multiple, Viral Epidemiological Monitoring Female Genotype Geography HIV Infections - drug therapy HIV Infections - epidemiology HIV Infections - transmission HIV Infections - virology HIV-1 - drug effects HIV-1 - genetics Humans Male Mexico - epidemiology Mutation Prevalence Retrospective Studies Reverse Transcriptase Inhibitors - pharmacology Reverse Transcriptase Inhibitors - therapeutic use Sequence Analysis, DNA Young Adult |
| title | HIV pretreatment drug resistance trends in three geographic areas of Mexico |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T16%3A33%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HIV%20pretreatment%20drug%20resistance%20trends%20in%20three%20geographic%20areas%20of%20Mexico&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Garc%C3%ADa-Morales,%20Claudia&rft.aucorp=HIVDR%20MexNet%20Group&rft.date=2017-11-01&rft.volume=72&rft.issue=11&rft.spage=3149&rft.epage=3158&rft.pages=3149-3158&rft.issn=0305-7453&rft.eissn=1460-2091&rft_id=info:doi/10.1093/jac/dkx281&rft_dat=%3Cproquest_cross%3E1945220554%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1945220554&rft_id=info:pmid/28961972&rfr_iscdi=true |